Halozyme Therapeutics in (halo 1 08/15/28)
13F holders, Q1 2026 (March 31)8holders +2
2new positions
0sold out
$1.26avg. 13F price*
At the end of Q1 2026, 8 institutions reported holding Halozyme Therapeutics in (halo 1 08/15/28) in their 13F filings, up 2 from Q4 2025. 2 opened new positions and 0 sold out. The largest holders were Absolute Investment Advisers, LLC ($18.0M), Ssi Investment Management LLC ($7.8M) and Ofi Invest Asset Management ($7.6M).
- Company
- Halozyme Therapeutics in (halo 1 08/15/28)
- CUSIP
- 40637HAF6
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $7.8M |
| Exits | 0 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 6,081,814 shares bought, net +6,081,814 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Absolute Investment Advisers, LLC | 2.11% | No change | 14,000,000 | $18.0M |
| Ssi Investment Management LLC | 0.64% | New | 6,079,000 | $7.8M |
| Ofi Invest Asset Management | 0.10% | No change | 6,800,000 | $7.6M |
| State of Wisconsin Investment Board | 0.01% | No change | 3,000,000 | $3.8M |
| Focus Partners Wealth | 0.00% | No change | 2,295,000 | $3.0M |
| Bank of New York Mellon Corp | 0.00% | No change | 610,000 | $786K |
| Loomis Sayles & Co. L P | 0.00% | Add +16.0% | 5,177 | $335K |
| Boussard & Gavaudan Investment Management LLP | 0.00% | New | 2,100 | $3K |
"% of holder's portfolio" is HALOZYME THERAPEUTICS IN (HALO 1 08/15/28)'s weight in each manager's 13F, not the share of Halozyme Therapeutics in (halo 1 08/15/28) the manager owns.